Business
Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
– Final Dataset from ARTISTRY-1 Clinical Trial to be Featured in an Oral Presentation – – Trial-in-Progress Posters From ARTISTRY-3, ARTISTRY-6 and ARTISTRY-7
About this update from Alkermes Plc
[{"type":"text","content":"– Final Dataset from ARTISTRY-1 Clinical Trial to be Featured in an Oral Presentation –\n– Trial-in-Progress Posters From ARTISTRY-3, ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented –\nDUBLIN, May 9, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of four abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually. The final dataset from the phase 1/2 ARTISTRY-1 clinical trial, evaluating the safety, tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA®), will be shared in an oral presentation. In addition, trial-in-progress posters from the ongoing ARTISTRY-3 trial and the potential registration-enabling studies ARTISTRY-6 and ARTISTRY-7 will be presented.\nDetails of the presentations are as follows:Oral PresentationAbstract: 2500Title: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1Presenter: Ulka N. Vaishampayan, M.D., Professor, Internal Medicine, Division of Hematology/Oncology, University of MichiganPresentation Session Date/Time: The oral presentation will take place on Saturday, June 4, 2022 from 1:15 – 4:15 p.m. CDT, during the session titled \"Developmental Therapeutics—Immunotherapy\"\nPoster PresentationsAbstract: TPS5609Title: ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancerPresenter: Thomas J. Herzog, M.D., Professor of Obstetrics and Gynecology, Deputy Director, University of Cincinnati Cancer Institute and Associate Director of GOG PartnersPresentation Session Date/Time: The poster will be presented on Saturday, June 4, 2022 from 1:15 – 4:15 p.m. CDT, during the \"Gynecologic Cancers\" poster session\nAbstract: TPS2684Title: ARTISTRY-3: Effect of nemvaleukin alfa with a less frequent IV dosing schedule as monotherapy and in combination with pembrolizumab and impact on the tumor microenvironment (TME) in patients (pts) with advanced solid tumorsP...